RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters

Douglas G. Widman, Tomohiro Ishikawa, Evandro R. Winkelmann, Ernesto Infante, Nigel Bourne, Peter W. Mason

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

West Nile virus (WNV) causes significant disease, yet no vaccines exist to prevent WN disease in humans. We have previously reported that RepliVAX WN is a safe and efficacious vaccine in mouse and hamster models of WN disease. Here, we report that vaccination of hamsters with RepliVAX WN induces antibody responses that remain stable for at least 6 months. Furthermore, animals challenged with virulent WNV 6 months after vaccination were protected from disease as well as those challenged 2 months post-vaccination, with no vaccinated animals succumbing to WNV challenge. These results indicate that RepliVAX is capable of inducing durable protective immunity after a single dose.

Original languageEnglish (US)
Pages (from-to)5550-5553
Number of pages4
JournalVaccine
Volume27
Issue number41
DOIs
StatePublished - Sep 18 2009

    Fingerprint

Keywords

  • Antibody
  • Hamster
  • Live-attenuated vaccine

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Cite this